NCT06082531 Effect of Platelet-rich Plasma (PRP) Injection on Knee Osteoarthritis
| NCT ID | NCT06082531 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xijing Hospital |
| Condition | Platelets-rich Plasma |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2023-09-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2023-09-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the safety and effectiveness of PRP injection therapy in the repair of osteoarthritis and periarticular soft tissue injury through a single-center, exploratory clinical study, and to provide a more reliable basis for the treatment of joint injury.
Eligibility Criteria
Inclusion Criteria: * The age range of the participants was 20 to 60 years old. Through a comprehensive clinical and imaging examination, it was conclusively determined that the individuals had knee osteoarthritis or experienced injuries to the cart, and meniscus surrounding the knee joint. * The preoperative routine tests and examinations revealed no contraindications. * Revised sentence: "Informed consent of the patient Exclusion Criteria: * The platelet count or function exhibits significant abnormalities、Systemic infection transmitted through the bloodstream. * Prolonged usage of anti-inflammatory drugs and systemic corticoid administration. * In injection site or damage to the skin. * Patients with tumors or undergoing radiotherapy and chemotherapy. * Pregnant or breastfeeding women. * Individuals with mental illnesses who are unable to cooperate with follow-up procedures. * Contraindications for MRI、Patients or their families do consent to participate in the study. * Other circumstances that render participation in the study unsuitable.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06082531 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 60 Years, studying Platelets-rich Plasma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06082531 currently recruiting?
Yes, NCT06082531 is actively recruiting participants. Contact the research team at xiyyllwyh@163.com for enrollment information.
Where is the NCT06082531 trial being conducted?
This trial is being conducted at Xi'an, China.
Who is sponsoring the NCT06082531 clinical trial?
NCT06082531 is sponsored by Xijing Hospital. The trial plans to enroll 300 participants.